$CRDF received 9 mentions over a 12-month period from 2 distinct FinTwit voices, with discussion concentrated in the biotech sector. @jacobplieth dominated the conversation with 8 mentions, while @adamfeuerstein contributed 1 mention. The first mention appeared on 2025-07-29, with the most recent activity on 2025-07-30, indicating recent heightened attention to the stock. The bulk of discussion centered on clinical trial developments related to onvansertib, Cardiff Oncology's lead candidate.